Chief financial officers across Nigeria’s major pharmaceutical manufacturers listed on the Nigerian Exchange are executing sharp balance-sheet adjustments to protect margins against volatile foreign exchange rates, surging energy expenses, and elevated domestic borrowing costs.
The domestic pharmaceutical market has experienced structural disruption over the past two years following macroeconomic shifts, including currency devaluation and the exit of multinational players such as GlaxoSmithKline and Sanofi from direct commercial operations in the country. These developments created larger domestic market share opportunities for indigenous drugmakers, but they also significantly inflated the cost of raw material importation and working capital.
Financial chiefs steering the sector are contending with an operating landscape where active pharmaceutical ingredients (APIs) and packaging inputs remain largely import-dependent, exposing corporate profit margins to foreign currency swings. At the same time, monetary policy tightening by the Central Bank of Nigeria has pushed benchmark lending rates to record highs, making local debt servicing increasingly expensive for capital-intensive manufacturing operations.
At May & Baker Nigeria Plc, Executive Director of Finance Ayodeji Aboderin oversees financial operations as the company expands local production lines while controlling operating overhead. Aboderin, a seasoned finance professional with extensive corporate experience across manufacturing and financial management, has focused on working capital discipline and debt containment as the company scales manufacturing at its Ota facility in Ogun State.
At Fidson Healthcare Plc, the largest domestic pharmaceutical producer by market value on the local exchange, the finance leadership team has concentrated on preserving gross margins through dynamic pricing and inventory management. The company, led financially by Imokhai Ehimare, who manages financial strategy and operational planning, has utilised domestic debt markets, including commercial paper programmes, to manage cash flow cycles while financing ongoing capacity expansions.
Similarly, Neimeth International Pharmaceuticals Plc has relied on its treasury and accounting executives to manage recapitalisation initiatives and production realignments following major investments in its manufacturing infrastructure at Amawbia, Anambra State. The company has had to balance high capital expenditure obligations against prolonged working capital turnover times in the retail drug distribution channel.
Balance Sheet Restructuring and Local API Sourcing Strategies
Managing liquidity has become the central focus for pharmaceutical finance directors because drug manufacturers require long inventory lead times to bring imported ingredients into finished goods. According to reporting on sector corporate leadership compiled by Nairametrics, corporate finance heads across the segment have had to negotiate extended supplier credit terms and reprice core product portfolios to mitigate margin contraction.
The financial burden has been compounded by Nigeria’s heavy reliance on external suppliers for active ingredients, with the country importing more than 70 percent of its finished medicines and almost all chemical precursors. When currency depreciation raised import costs, manufacturers faced severe gross margin compression unless they passed expenses on to consumers whose disposable purchasing power was already constrained by general inflation.
To survive the squeeze, CFOs have pursued multiple funding strategies, including refinancing high-cost bank facilities into lower-cost development loans where eligible, and leveraging federal intervention funds designed to promote healthcare industrialisation. Companies have also reassessed trade credit agreements with distributors to reduce payment defaults and accelerate cash collection cycles.
Regulatory interventions offer a potential financial buffer for corporate treasurers in the sector. The implementation of the federal government’s zero-tariff executive order on pharmaceutical raw materials and specialised machinery is intended to reduce customs duties and port clearance bottlenecks, providing direct relief to operating margins once fully operationalised across ports of entry.
Looking ahead, pharmaceutical finance executives are expected to direct capital expenditure toward backward integration and contract manufacturing partnerships with international pharmaceutical brands seeking local production partners. The success of these listed manufacturers over coming quarters will depend on how effectively their financial leadership manages foreign exchange exposure while securing sustainable long-term capital for plant modernisations.
Explore more Companies stories and analysis from Business Elites Africa.
